Table 2.
Univariate analysis for significant transplant outcomes at 12 years.
| Variables | Median (95% CI) | ||||
|---|---|---|---|---|---|
| OS | PFS | GRFS | TRM | RI | |
| Recipient age | |||||
| <60 years | 50.1% (38.7–60.5) | 39.3% (28.7–49.8) | 24.6% (15.8–34.4) | 16.2% (9.2–25.1) | 44.4% (33.3–54.9) |
| ≥60 years | 16.5% (5.3–33) | 6.7% (0.6–23.7) | 6.9% (0.7–24.3) | 41.6% (22.1–60) | 51.1% (27.3–70.7) |
| p = 0.001 | p = 0.019 | p = 0.199 | p = 0.004 | p = 0.916 | |
| DRI | |||||
| Low/intermediate | 46.1% (35.2–56.4) | 38.7% (28.4–48.8) | 25.1% (16.5–24.6) | 22.1% (14–31.5) | 39.1% (28.8–49.3) |
| High/very high | 23.8% (8.7–43.1) | 4.8% (0.3–19.7) | 4.8% (0.3–19.7) | 23.8% (8.2–43.9) | 71.4% (44–87.1) |
| p = 0.015 | p < 0.001 | p = 0.008 | p = 0.986 | p = 0.002 | |
| Donor type | |||||
| MRD | 48.5% (33.8–61.8) | 43.1% (28.9–56.4) | 21.7% (11.5–33.9) | 14.8% (6.4–26.6) | 42% (28.1–55.3) |
| MUD | 32.7% (18.2–48.2) | 11.9% (3.6–25.7) | 12.2% (3.7–26) | 30.8% (16.4–46.3) | 57.1% (37.9–72.4) |
| MMUD | 40.9% (20.9–60.1) | 36.4% (17.4–55.7) | 31.8% (14.2–51.1) | 27.3% (10.7–47) | 36.4% (16.8–56.3) |
| p = 0.161 | p = 0.016 | p = 0.331 | p = 0.097 | p = 0.373 | |
| ATLG | |||||
| Yes | 35.8% (23.7–48) | 21.8% (12.2–33.3) | 21.7% (11.5–33.9) | 29.4% (18.2–41.5) | 48.6% (35–61) |
| No | 48.5% (33.8–61.8) | 43.1% (28.9–56.4) | 20.3% (11–31.5) | 14.8% (6.4–26.6) | 42% (28.1–55.3) |
| p = 0.073 | p = 0.02 | p = 0.537 | p = 0.031 | p = 0.731 | |
Outcomes were not statistically different if patients were grouped according to HCT-CI score, host/donor CMV mismatch, or stem cell source (not shown).
CI, confidence interval; OS, overall survival; PFS, progression-free survival; GRFS, graft-versus-host-free/relapse-free survival; TRM, transplant-related mortality; RI, relapse incidence; DRI, disease risk index; MRD, matched related donor; MUD, matched unrelated donor; MMUD, 9/10-mismatched unrelated donor; ATLG, anti T-lymphocyte globulin.
Bold values were statistically significant.